Pfizer compresses as J&J expands ops structure

Pfizer's new CEO Ian Read has flattened the drug giant's org chart, eliminating the global head level. Unit heads will report to him instead, to speed decision-making. Tony Maddaluna will take over global manufacturing early next year when Nat Ricciardi retires. Meanwhile, J&J head Bill Weldon has added a layer at the board level. Sheri McCoy, currently global chairman for the pharma division, will become a vice chairman for the executive committee. She's being groomed as a potential successor to Weldon and will sit atop the manufacturing and quality-control overhaul at McNeil. Article | Story

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.